"Nefecon®","Ambrisentan"
25K183-001
Approved small_molecule active
Quick answer
"Nefecon®","Ambrisentan" for IgA Nephropathy is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- IgA Nephropathy
- Phase
- Approved
- Modality
- small_molecule
- Status
- active